Bacterial enzymes and structural proteins

Bacterial enzymes and structural proteins constitute the fundamental molecular targets for antimicrobial therapy, encompassing a diverse array of proteins essential for bacterial viability and replication [1.1.1, 1.3.4]. These targets are strategically selected based on their essentiality to the pathogen and their structural divergence from human homologs, which minimizes host toxicity [1.2.1, 1.3.4]. Key enzymatic targets include penicillin-binding proteins (PBPs), which catalyze the cross-linking of the peptidoglycan cell wall, and DNA gyrase and topoisomerase IV, which manage DNA supercoiling during replication [1.1.4, 1.2.3, 1.3.1]. Structural targets primarily include the bacterial ribosome (30S and 50S subunits), responsible for protein translation, and the cell membrane components like lipopolysaccharides in Gram-negative bacteria [1.1.1, 1.1.3, 1.2.1]. Antibiotics such as beta-lactams, fluoroquinolones, and aminoglycosides bind to these sites to inhibit critical processes, leading to bacterial growth arrest or cell death [1.1.2, 1.1.4, 1.3.2]. The clinical utility of targeting these proteins is frequently challenged by the emergence of resistance mechanisms, including target site mutations, enzymatic drug inactivation, and increased efflux [1.3.1, 1.3.3, 1.4.2].

Other names

Bacterial drug targetsProkaryotic proteinsAntibiotic targetsBacterial molecular targets

Antibiotics target these proteins to disrupt essential bacterial processes: beta-lactams inhibit cell wall synthesis by binding to PBPs; fluoroquinolones inhibit DNA replication by targeting DNA gyrase and topoisomerase IV; macrolides and aminoglycosides inhibit protein synthesis by binding to ribosomal subunits; and sulfonamides disrupt metabolic pathways by inhibiting folate synthesis enzymes [1.1.1, 1.1.4, 1.3.1, 1.3.2].